Gemphire Therapeutics Inc (GEMP) Stock Price & Overview

Name: Gemphire Therapeutics Inc (GEMP) overall Analysis
Brand: Gemphire Therapeutics Inc
Rating: 0.5 (3 reviews)

NASDAQ:GEMP

0.3

0 (-0.37%)

At close: Dec 30, 2019

0.3

0 (0%)

After Hours: 12/30/2019, 9:09:12 PM

The current stock price of GEMP is 0.3 null. Today GEMP is down by -0.37%. In the past month the price decreased by -16.43%. In the past year, price decreased by -64.07%.

GEMP Key Statistics

52-Week Range0.238 - 1.485

1-Month Range0.238 - 0.3869

Market Cap: 4.462M
P/E: N/A
Fwd P/E: N/A
EPS (TTM): -1.16
Dividend Yield: N/A

GEMP Stock Performance

Today

-0.37%

1 Week

N/A

1 Month

-16.43%

3 Months

-14.29%

Longer-term

6 Months -60.53%

1 Year -64.07%

2 Years N/A

3 Years N/A

5 Years N/A

10 Years N/A

GEMP Stock Chart

Gemphire Therapeutics Inc / GEMP Daily stock chart

GEMP Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to GEMP. When comparing the yearly performance of all stocks, GEMP is a bad performer in the overall market: 96.12% of all stocks are doing better.

Chartmill TA Rating

Chartmill Setup Rating

GEMP Full Technical Analysis Report

GEMP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GEMP. Both the profitability and financial health of GEMP have multiple concerns.

Chartmill FA Analysis

Valuation

Growth

Profitability

Health

Dividend

GEMP Full Fundamental Analysis Report

GEMP Earnings

Next Earnings DateN/A

Last Earnings DateN/A

GEMP Earnings History

GEMP Forecast & Estimates

Analysts

Analysts0

Price TargetN/A

EPS Next Y-46.2%

Revenue Next YearN/A

GEMP Forecast & Estimates

GEMP Financial Highlights

Over the last trailing twelve months GEMP reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 53.6% compared to the year before.

Income Statements

Revenue(TTM)N/A

Net Income(TTM)-13.81M

		Industry Rank	Sector Rank
PM (TTM)	N/A
ROA	-674.17%
ROE	N/A
Debt/Equity	-6.24

Chartmill High Growth Momentum

EPS Q2Q%57.45%

Sales Q2Q%N/A

EPS 1Y (TTM)53.6%

Revenue 1Y (TTM)N/A

GEMP financials

GEMP Ownership

Ownership

Inst Owners17.53%

Shares14.87M

Float10.80M

Ins Owners25.01%

Short Float %N/A

Short RatioN/A

GEMP Ownership

About GEMP

Company Profile

Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan.

Company Info

Gemphire Therapeutics Inc

17199 N. LAUREL PARK DRIVE SUITE 401

LIVONIA MI 48152

CEO: Steven Gullans

Phone: 734-245-1700

Gemphire Therapeutics Inc / GEMP FAQ

What does GEMP do?

What is the current price of GEMP stock?

The current stock price of GEMP is 0.3 null. The price decreased by -0.37% in the last trading session.

Does Gemphire Therapeutics Inc pay dividends?

GEMP does not pay a dividend.

What is the ChartMill technical and fundamental rating of GEMP stock?

GEMP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.

Would investing in Gemphire Therapeutics Inc be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GEMP.

Who owns Gemphire Therapeutics Inc?

You can find the ownership structure of Gemphire Therapeutics Inc (GEMP) on the Ownership tab.